Newscast – Page 182 – media

US nod for CSL Behring’s HAE prevention therapy

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary (HAE) attacks in adolescent and adults.
- Source: pharmatimes
- 457
- June 23, 2017
HAE inhibitor New Approvals
EU regulators review Novartis’ migraine drug

An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
- Source: pharmatimes
- 1,081
- June 22, 2017
antibody Clinical Trials erenumab EU New Approvals WHO
Owlstone’s search into breath biomarkers of cancer

Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
- Source: pharmatimes
- 552
- June 15, 2017
cancer Clinical Trials diagnostic therapy
Merck pauses Keytruda studies to assess patient deaths

Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
- Source: pharmatimes
- 513
- June 13, 2017
asthma Clinical Trials keytruda
Pioneering prostate biopsy device wins NIHR award

A new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR).
- Source: pharmatimes
- 543
- June 13, 2017
biopsy device Market Views NIHR
First PhIII trial of AbbVie’s upadacitinib a success

AbbVie’s upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
- Source: Pharmatimes
- 543
- June 9, 2017
Clinical Trials rheumatoid arthritis
FDA approval granted to Emmaus for sickle cell therapy

Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
- Source: fiercebiotech
- 562
- June 9, 2017
Company Insight FDA therapy
Aspen Pharmacare hit by EU antitrust cancer drug price probe

Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
- Source: pharmatimes
- 632
- May 16, 2017
cancer Company Insight EU
One in three RA patients rejecting meds because of cost

One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
- Source: pharmatimes
- 554
- May 14, 2017
Market Views NRAS PPC
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 631
- May 10, 2017
cancer clinic Company Insight FDA gentic

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.